Nordea Investment Management AB reduced its Pfizer stock holdings by 20.9% in the fourth quarter, selling over 1.27 million shares and holding about 4.82 million shares valued at $120 million. Despite this, Pfizer reported better-than-expected quarterly earnings and ongoing progress in its oncology pipeline, which has attracted recent analyst upgrades and a positive outlook from HSBC. However, the stock faces mixed sentiment with some analysts rating it as a hold or underweight, and Pfizer advising shareholders to reject a mini-tender offer. The company's diverse portfolio and recent clinical successes keep it in focus for investors, though near-term upside remains uncertain.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
